Literature DB >> 24500765

[The role of opioids in the treatment of primary headache disorders].

A Totzeck1, C Gaul.   

Abstract

There is no sufficient evidence for opioids in the acute treatment of primary headache disorders. Controlled clinical trials using triptans as comparator are missing. Data show high frequent headache recurrence, typical side effects of opioids, increased risk of chronification, and development of addiction in primary headache patients treated with opioids. Chronic headache patients with opioid therapy often experience lengthy withdrawal treatment. On the basis of the current scientific data, opioids should be avoided in acute and prophylactic treatment of primary headache disorders.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24500765     DOI: 10.1007/s00482-013-1380-4

Source DB:  PubMed          Journal:  Schmerz        ISSN: 0932-433X            Impact factor:   1.107


  49 in total

1.  OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial.

Authors:  S K Aurora; D W Dodick; C C Turkel; R E DeGryse; S D Silberstein; R B Lipton; H C Diener; M F Brin
Journal:  Cephalalgia       Date:  2010-03-17       Impact factor: 6.292

2.  Cost of health care among patients with chronic and episodic migraine in Canada and the USA: results from the International Burden of Migraine Study (IBMS).

Authors:  Michael Stokes; Werner J Becker; Richard B Lipton; Sean D Sullivan; Teresa K Wilcox; Leandra Wells; Aubrey Manack; Irina Proskorovsky; Jonathan Gladstone; Dawn C Buse; Sepideh F Varon; Peter J Goadsby; Andrew M Blumenfeld
Journal:  Headache       Date:  2011 Jul-Aug       Impact factor: 5.887

3.  Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial.

Authors:  Stephen D Silberstein; Richard B Lipton; David W Dodick; Frederick G Freitag; Nabih Ramadan; Ninan Mathew; Jan L Brandes; Marcelo Bigal; Joel Saper; Steven Ascher; Donna M Jordan; Steven J Greenberg; Joseph Hulihan
Journal:  Headache       Date:  2007-02       Impact factor: 5.887

4.  Dose effectiveness and safety of butorphanol in acute migraine headache.

Authors:  R M Elenbaas; C U Iacono; K J Koellner; J P Pribble; M Gratton; G Racz; R P Evens
Journal:  Pharmacotherapy       Date:  1991       Impact factor: 4.705

5.  Metoclopramide versus hydromorphone for the emergency department treatment of migraine headache.

Authors:  Justin D Griffith; Mark B Mycyk; Demetrios N Kyriacou
Journal:  J Pain       Date:  2007-11-05       Impact factor: 5.820

6.  EFNS guideline on the drug treatment of migraine--revised report of an EFNS task force.

Authors:  S Evers; J Afra; A Frese; P J Goadsby; M Linde; A May; P S Sándor
Journal:  Eur J Neurol       Date:  2009-09       Impact factor: 6.089

Review 7.  Use of narcotic analgesics in the emergency department treatment of migraine headache.

Authors:  I Colman; A Rothney; S C Wright; B Zilkalns; B H Rowe
Journal:  Neurology       Date:  2004-05-25       Impact factor: 9.910

8.  Transformed migraine and medication overuse in a tertiary headache centre--clinical characteristics and treatment outcomes.

Authors:  M E Bigal; A M Rapoport; F D Sheftell; S J Tepper; R B Lipton
Journal:  Cephalalgia       Date:  2004-06       Impact factor: 6.292

Review 9.  Antinociceptive and nociceptive actions of opioids.

Authors:  Michael H Ossipov; Josephine Lai; Tamara King; Todd W Vanderah; T Philip Malan; Victor J Hruby; Frank Porreca
Journal:  J Neurobiol       Date:  2004-10

10.  Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study.

Authors:  H-C Diener; G Bussone; J C Van Oene; M Lahaye; S Schwalen; P J Goadsby
Journal:  Cephalalgia       Date:  2007-04-18       Impact factor: 6.292

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.